Combination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma

Area of Science:

• Oncology
• Dermatology
• Immunology

Background:

• Metastatic melanoma is an aggressive skin cancer with a poor prognosis.
• Current treatments like oncogene-targeted therapy and immunotherapy have limitations, including acquired resistance and limited response rates.
• Neither targeted therapy nor immunotherapy alone provides durable clinical responses for most patients.

Purpose of the Study:

• To explore the synergistic antitumor effects of combining targeted therapy and immunotherapy for metastatic melanoma.
• To identify strategies for improving therapeutic effectiveness and reducing toxicity in metastatic melanoma treatment.
• To elucidate the complex interactions between targeted therapy and immunotherapy in melanoma.

Main Methods:

• Review of preclinical studies and clinical trials investigating combination therapies.
• Analysis of mechanisms underlying acquired resistance to targeted therapy.
• Evaluation of immune responses elicited by immunotherapy.

Main Results:

• Combination therapy demonstrates synergistic antitumor effects in metastatic melanoma.
• Targeted therapy offers rapid responses but faces resistance; immunotherapy provides long-term regression but has limited response rates.
• The complementary nature of these treatments suggests a promising therapeutic strategy.

Conclusions:

• Combining targeted therapy and immunotherapy presents a promising strategy for treating metastatic melanoma.
• Further research is needed to understand the multifaceted interplay between these approaches for optimal clinical application.
• Optimizing combination regimens can enhance efficacy and reduce toxicity in patients with advanced skin cancer.